GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Current Accrued Expense

LTR Pharma (ASX:LTP) Current Accrued Expense : A$0.00 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Current Accrued Expense?

LTR Pharma's Current Accrued Expense for the quarter that ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma Current Accrued Expense Historical Data

The historical data trend for LTR Pharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Current Accrued Expense Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Current Accrued Expense
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Current Accrued Expense - - -

LTR Pharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

LTR Pharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Current Accrued Expense
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines